Member Info for Rokerpark68

For me this is a positive RNS which neatly pulls together all the good recent progress the company has made in both therapeutics and diagnostics. I feel a lot of the LFT "hype" has run its course, which I think is a good thing as investors should start focusing more on the full range of Avacta's activities. The reality is that LFT sales are going to be a nice-to-have rather than company defining. So be it. Yes, AS was obviously rash in raising expectations on LFT sales so much, and with hindsight I am not happy at all with that, but overall Avacta still has an enormous amount going for it.

If you really read the full RNS in detail what the company has achieved is very impressive. Yes, this is still a very high-risk investment and investors should size it in their portfolios accordingly, but IMO the outlook is very exciting for the next two years or so and beyond. It's easy to knock AS and the board but I think sometimes investors don't always understand how difficult it is to run a business like this. Avacta is operating in a very complex and competitive business environment with highly sophisticated products.

I have been in Avacta since April 2020 so have experienced the ups and downs - but if anything today I am a buyer.

For what it's worth, my average price is 54p. I top-sliced around 94p a few months ago but I have decided to run the rest of the holding given the momentum and news flow.

I never discuss specific share price targets on boards, but what I would say is that I would be very surprised and disappointed if SRC didn't do well over the next year or two given its good market position, exciting recent acquisition, positive industry outlook and high-quality management. So unless it runs up very quickly in the short-term (which may then create the justification for another modest profit-taking) I am happy to be patient.

Interesting Reach announcement this morning - I do like the way Sigmaroc is positioning itself as a low carbon operator. Very sensible and innovative.

A couple of the TR1s just reflect the impact of the large new share issue and the fact that some significant existing investors did not actually add to their holding in the fund raising.

Reassuring to see such a strong share price performance even after a large placing - a good indicator that market sentiment is very positive.

I'd be surprised if we saw any dividends any time soon given, as you say, they are still in acquisition and investment mode.

Nordkalk does seem to be very cash-generative - perhaps that will be the future engine for pay-outs, but I can't help feeling that SRC is likely to be sold itself before too long if it continues to deliver.

Hi ihalliwell10

Couldn't agree more with your comments. This business has excellent momentum and is going to benefit significantly from infra demand over the next few years. I really like the CEO too - concise and decisive.

Excellent announcement this morning - strong performance and a very positive outlook. Currently one of my favourite direct holdings.

Likewise letsbecool, and good luck with GC!

See you on other boards I hope.

Roker

Hi SK

Always enjoyed our exchanges.

Yes, it can be a small world.

All the very best

Roker

Nearly bought a house in Aldborough when we came back north 2 years ago, but I'm from the Harrogate area originally so we decided to come back to the town. Love it.

Used to play football against KJS in Knaresborough and my best mate at school lived on Waterside.

ATB

Hi Greend100

I go past that building when I walk to the ground on Wetherby Road! Is she a Harrogate lass?

I went to the Rochdale game the other week which they won 3-2 - it was great to be back in the ground but half the team have COVID at the moment so they can't play again for a while.

Good luck with TILS - I always found your posts hugely helpful and interesting.

Perhaps see you on another board soon.

ATB

Morning all,

I sold the last small tranche of my TILS holding a month or so ago - unfortunately I have decided I no longer trust the BoD and for me it's currently not worth the risk of waiting to see whether the science finally comes through.

I hope Accustem gets sorted out. Basically my profit on my TILS investment is purely a question of what Accustem is finally worth, if I ever get proper liquidity for my holding. At the moment I regard it as valueless, which will certainly be the case if GC finds a way to dilute other Accustem holders to oblivion when the business raises finance.

I've thoroughly enjoyed the discussions with a number of you , especially during last year. I'm sure you know who you are.

GLA all - I'm looking forward to following the drama here but no longer as a contributor!

Best
Rokerpark68

@Mambamentality

Just to point out that a share consolidation has no direct impact on valuation. After it's done, you have the same valuation, fewer shares but a correspondingly higher share price per share.

The idea is to make the share price look more like its peers so that the company doesn't immediately look like a poor cousin.

@Lasvelas

I wasn't blaming ST at the IC, I was just observing that as a professional tipster he came a cropper on VLG this week.

Thanks for reminding me that investing in shares carries risk - really useful insight.

It's a very good thing they managed to complete the two recent acquisitions before they had to disclose what was happening with the sanitiser business and Chinese order.

I take consolation from the fact that the core business and the new acquisitions still look good.

All a bit embarrassing for ST at the IC.

I have been a holder for over a year and overall think that the CEO and his team have navigated a very difficult and fluid business environment quite well.

Yesterday's presentation was by far the most reassuring I have seen over the last 12 months - I think the company is now well-positioned to make progress in all its businesses. You could see how confident the CEO is now.

How this all translates into share price progression we will have to wait and see, but sitting here today I am glad I have held on to my holding.

This looks like another attractive acquisition from both a strategic and a financial perspective. It seems to me VLG are putting in place the platform for some solid growth over the next few years. Also, I think it will become an increasingly interesting takeover target as its product portfolio matures.

Wonder what their cash burn rate is so far this year?

I wonder when we will hear about what's happening with the Takanawa strategic initiative in relation to Milciclib in Asia. The RNS announcing the initiative was released on 5 May so we are getting on for three months now. Perhaps it's unrealistic to expect news for another few months yet.